Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2026 07:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

41.6% Absolute Difference in the Cema-Cel Arm Over the Observation Arm Exceeded Clinically Meaningful Benchmark Based on Literature of 25-30%MRD Reduction Occurred Rapidly Following Cema-Cel Treatment...
April 13, 2026 07:30 ET | Source: BullFrog AI Holdings, Inc.

BullFrog AI Provides Business Update: Strengthened Balance Sheet Supports Continued Execution as Company Aims to Ramp Commercial Activity with Global Pharmaceutical and Biotechnology Partners

GAITHERSBURG, Md., April 13, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (Nasdaq: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence and...
April 13, 2026 07:30 ET | Source: MediWound Ltd.

Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement

Newly Published U.S. Expert Consensus Aligns with MediWound’s Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive...
April 13, 2026 07:05 ET | Source: Kraig Biocraft Laboratories

From Milestone to Momentum: Kraig Biocraft Leadership Travels to South East Asia Following Record-Setting 1.3 Metric Ton Recombinant Spider Silk Cocoon Production Cycle

Kraig Labs (OTCQB: KBLB) senior management is in ASEAN to build on the momentum of its recently announced record-setting spider silk production
April 13, 2026 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track...
April 13, 2026 07:00 ET | Source: ImageneBio, Inc.

ImageneBio Announces $30 Million Private Placement

Private placement led by Coastlands Capital with participation from additional new and existing investors Proceeds will support further development of IMG-007 in alopecia areata and late-stage...
April 13, 2026 07:00 ET | Source: Spyre Therapeutics, Inc.

Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints...
April 13, 2026 07:00 ET | Source: OXB

OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture

New expedited service line designed for biotechs with timeline constraints, launched in response to client demandCan accelerate timeline to GMP manufacturing by up to nine months, driven by key...
April 13, 2026 06:50 ET | Source: ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules

PRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200...
April 13, 2026 06:30 ET | Source: Telix Pharmaceuticals Limited

Telix and Regeneron Announce Strategic Radiopharma Collaboration

Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model.Collaboration combines Telix’s expertise in...